Riskpilot← Back to searchSign inGet full accessNORWEGIANPHARMAFLUIDS AS
ASActiveOrg 917725918Vallerudveien 29, 1476 RastaActivities of agents involved in the wholesale of other particular products · NACE 4618Est. 20160 employees
Revenue 2024
NOK 0
EBITDA margin
—
-62% vs 2023
Equity ratio
446033.3%
Financial strength
Net profit 2024
NOK -9K
-62% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -9K | -62% |
| Net profit | NOK -9K | -62% |
| Total assets | NOK -6 | -130% |
| Equity | NOK -27K | -48% |
| Employees | 0 | — |
Legal name
NORWEGIANPHARMAFLUIDS AS
Org number
917725918
Legal form
Aksjeselskap
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
15. september 2016
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Agentur, engros, kjøp, salg, produksjon, forskning, utvikling, laboratorium virksomhet, eksport, import, handel, industri, kjøp og salg av aksjer og andeler i andre selskaper og fast eiendom og hva herved står i forbindelse.
Address
Vallerudveien 29, 1476 Rasta
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −3 | −14 | −5 | −4 | −8 | −6 | −8 | −5 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −3 | −14 | −5 | −4 | −8 | −6 | −8 | −5 | −9 |
| Net financials | 0 | 0 | 0 | 0 | −0 | −0 | 0 | 0 | −0 |
| Profit before tax | −3 | −14 | −5 | −4 | −8 | −6 | −8 | −5 | −9 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 | −14 | −5 | −4 | −8 | −6 | −8 | −5 | −9 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 21 | 7 | 2 | 11 | 7 | 2 | −0 | 0 | −0 |
| Equity | 21 | 7 | 2 | −2 | −10 | −16 | −24 | −18 | −27 |
| Long-term debt | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 24 | 33 |
| Short-term debt | 0 | 0 | 0 | 2 | 17 | 19 | 24 | −6 | −6 |
| Total debt | 0 | 0 | 0 | 12 | 17 | 19 | 24 | 18 | 27 |
EBITDA margin
-871200.0%
This company
15.8%
Market median
-5514024% vs market
20162024
Equity ratio
-2676200.0%
This company
38.2%
Market median
-7005859% vs market
20162024
Return on equity
-871800.0%
This company
18.4%
Market median
-4738143% vs market
20162024
Net profit margin
-871800.0%
This company
8.1%
Market median
-10763063% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20162024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-08-29 – 2016-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 17.3% | 17.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 | |
| Individual | 10.3% | 10.3% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORWEGIANPHARMAFLUIDS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|